Skip to search formSkip to main contentSkip to account menu

VX-509

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
SAT0227 The Effect of Deuteration of VX-509 (Decernotinib) on Drug-Drug Interactions (DDI) with Midazolam
Background VX-509 is an oral selective Janus Kinase 3 inhibitor that has been studied in patients with rheumatoid arthritis (RA… 
2014
2014
OP0151 A Phase 2B, 24-Week Study of VX-509 (DECERNOTINIB), an Oral Selective Janus Kinase 3 Inhibitor, in Combination with Background Methotrexate in Rheumatoid Arthritis
Background VX-509 is an oral selective JAK3 inhibitor being evaluated for the treatment of rheumatoid arthritis (RA). This was a… 
2014
2014
THU0242 Vx-509 (DECERNOTINIB) Treatment Reduces Levels of Markers for Immune Activation, Bone Degradation and Inflammation but not Interferon Signaling in Patients with Rheumatoid Arthritis
Background Janus kinase 3 (JAK3) plays a critical role in gamma-chain cytokine signal transduction and is essential for… 
2013
2013
THU0160 The Effect of VX-509, a Selective Oral Jak3 Inhibitor, on Plasma Biomarkers of Disease Activity in Patients with Rheumatoid Arthritis
Background Janus kinase 3 (JAK3) plays a critical role in intracellular signal transduction and is required for activation of… 
2013
2013
THU0141 Biomarker assessment of VX-509, an investigational selective JAK3 inhibitor, in healthy volunteers
Background The IL-2 cytokine receptor family plays an important role in lymphocyte development, survival, and T cell-mediated… 
Review
2013
Review
2013
SP0169 JAK inhibition in patients with rheumatoid arthritis
The Janus Kinase (JAK) group of tyrosine kinases are intracellular signaling molecules which become phosphorylated upon… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)